Rafferty Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-58,237
| Closed | -$3.13M | – | 1136 |
|
|
2022
Q3 | $3.13M | Buy |
58,237
+13,327
| +30% | +$716K | 0.03% | 408 |
|
|
2022
Q2 | $2.5M | Sell |
44,910
-31,745
| -41% | -$1.77M | 0.02% | 421 |
|
|
2022
Q1 | $5.38M | Buy |
76,655
+17,932
| +31% | +$1.26M | 0.03% | 374 |
|
|
2021
Q4 | $5.66M | Buy |
58,723
+22,229
| +61% | +$2.14M | 0.03% | 337 |
|
|
2021
Q3 | $3.17M | Buy |
36,494
+2,669
| +8% | +$232K | 0.02% | 446 |
|
|
2021
Q2 | $2.77M | Buy |
33,825
+1,417
| +4% | +$116K | 0.02% | 533 |
|
|
2021
Q1 | $3.08M | Buy |
32,408
+16,312
| +101% | +$1.55M | 0.02% | 470 |
|
|
2020
Q4 | $999K | Sell |
16,096
-15,158
| -48% | -$941K | 0.01% | 493 |
|
|
2020
Q3 | $1.86M | Buy |
31,254
+16,037
| +105% | +$953K | 0.02% | 440 |
|
|
2020
Q2 | $1.06M | Buy |
15,217
+8,242
| +118% | +$575K | 0.02% | 527 |
|
|
2020
Q1 | $316K | Sell |
6,975
-52,334
| -88% | -$2.37M | 0.01% | 422 |
|
|
2019
Q4 | $3.86M | Sell |
59,309
-47,335
| -44% | -$3.08M | 0.06% | 171 |
|
|
2019
Q3 | $6.62M | Buy |
106,644
+29,128
| +38% | +$1.81M | 0.1% | 111 |
|
|
2019
Q2 | $5.52M | Buy |
77,516
+2,468
| +3% | +$176K | 0.1% | 140 |
|
|
2019
Q1 | $5.89M | Buy |
+75,048
| New | +$5.89M | 0.09% | 112 |
|